Design of Tracers in Fluorescence Polarization Assay for Extensive Application in Small Molecule Drug Discovery.

Development of fluorescence polarization (FP) assays, especially in a competitive manner, is a potent and mature tool for measuring the binding affinities of small molecules. This approach is suitable for high-throughput screening (HTS) for initial ligands and is also applicable for further study of the structure-activity relationships (SARs) of candidate compounds for drug discovery. Buffer and tracer, especially rational design of the tracer, play a vital role in an FP assay system. In this perspective, we provided different kinds of approaches for tracer design based on successful cases in recent years. We classified these tracers by different types of ligands in tracers, including peptide, nucleic acid, natural product, and small molecule. To make this technology accessible for more targets, we briefly described the basic theory and workflow, followed by highlighting the design and application of typical FP tracers from a perspective of medicinal chemistry.

[1]  Wei Wang,et al.  Discovery of 2H-Indazole-3-carboxamide Derivatives as Novel Potent Prostanoid EP4 Receptor Antagonists for Colorectal Cancer Immunotherapy. , 2023, Journal of medicinal chemistry.

[2]  R. Hoffmann,et al.  A High-Throughput Fluorescence Polarization-Based Assay for the SH2 Domain of STAT4 , 2022, Methods and protocols.

[3]  O. Rossanese,et al.  Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays , 2022, Scientific Reports.

[4]  Helder Veras Ribeiro Filho,et al.  Discovery and structural characterization of chicoric acid as a SARS-CoV-2 nucleocapsid protein ligand and RNA binding disruptor , 2022, Scientific Reports.

[5]  G. Besra,et al.  Quantitative affinity measurement of small molecule ligand binding to major histocompatibility complex class-I–related protein 1 MR1 , 2022, The Journal of biological chemistry.

[6]  C. Fierke,et al.  Gambogic acid and juglone inhibit RNase P through distinct mechanisms , 2022, The Journal of biological chemistry.

[7]  G. Popowicz,et al.  Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery. , 2022, Journal of medicinal chemistry.

[8]  C. Schofield,et al.  In Situ Inhibitor Synthesis and Screening by Fluorescence Polarization: An Efficient Approach for Accelerating Drug Discovery , 2022, Angewandte Chemie.

[9]  Yajun Zhang,et al.  Small-Molecule PROTACs for Cancer Immunotherapy , 2022, Molecules.

[10]  Shaoyong Lu,et al.  Rational design of a sensitivity-enhanced tracer for discovering efficient APC–Asef inhibitors , 2022, Nature Communications.

[11]  S. Chi,et al.  Application of nanopore sensors for biomolecular interactions and drug discovery. , 2022, Chemistry, an Asian journal.

[12]  J. Bushweller,et al.  Small-Molecule Inhibitors of the MLL1 CXXC Domain, an Epigenetic Reader of DNA Methylation. , 2022, ACS medicinal chemistry letters.

[13]  Yan Fan,et al.  Discovery of a potent, selective and cell active inhibitor of m6A demethylase ALKBH5. , 2022, European journal of medicinal chemistry.

[14]  M. Tian,et al.  Application of per-Residue Energy Decomposition to Design Peptide Inhibitors of PSD95 GK Domain , 2022, Frontiers in Molecular Biosciences.

[15]  Lei Wang,et al.  Methods for the Discovery and Identification of Small Molecules Targeting Oxidative Stress-Related Protein–Protein Interactions: An Update , 2022, Antioxidants.

[16]  K. Lepikhov,et al.  First Small-Molecule Inhibitors Targeting the RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy. , 2022, ACS chemical biology.

[17]  Minyong Li,et al.  Discovery of small-molecule fluorescent probes for C-Met. , 2022, European journal of medicinal chemistry.

[18]  M. Pazgier,et al.  Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression , 2021, Acta pharmaceutica Sinica. B.

[19]  L. Zhong,et al.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives , 2021, Signal Transduction and Targeted Therapy.

[20]  Ina Rothenaigner,et al.  Brief Guide: Experimental Strategies for High-Quality Hit Selection from Small-Molecule Screening Campaigns , 2021, SLAS discovery : advancing life sciences R & D.

[21]  I. Pavlinov,et al.  Development of a High-Throughput, Compound-Multiplexed Fluorescence Polarization Assay to Identify ATG5–ATG16L1 Protein–Protein Interaction Inhibitors , 2021, SLAS discovery : advancing life sciences R & D.

[22]  Peng Wu,et al.  Trisubstituted Pyrrolinones as Small-Molecule Inhibitors Disrupting the Protein–RNA Interaction of LIN28 and Let-7 , 2021, ACS medicinal chemistry letters.

[23]  R. Bauer,et al.  Natural products in drug discovery: advances and opportunities , 2021, Nature Reviews Drug Discovery.

[24]  Taosheng Chen,et al.  Development of BODIPY FL VH032 as a High-Affinity and Selective von Hippel–Lindau E3 Ligase Fluorescent Probe and Its Application in a Time-Resolved Fluorescence Resonance Energy-Transfer Assay , 2020, ACS omega.

[25]  Lei Chang,et al.  Neuroprotective Effect of N-Cyclohexylethyl-[A/G]-[D/E]-X-V Peptides on Ischemic Stroke by Blocking nNOS-CAPON Interaction. , 2020, ACS chemical neuroscience.

[26]  Mingjie Zhang,et al.  Identification of Novel Fragments Binding to the PDZ1‐2 Domain of PSD‐95 , 2020, ChemMedChem.

[27]  M. Baud,et al.  Current strategies for the design of PROTAC linkers: a critical review , 2020, Exploration of targeted anti-tumor therapy.

[28]  I. Coin,et al.  Capturing Peptide–GPCR Interactions and Their Dynamics , 2020, Molecules.

[29]  K. Ohno,et al.  Binding Assays Using a Benzofurazan-Labeled Fluorescent Probe for Estrogen Receptor-Ligand Interactions. , 2020, Chemical & pharmaceutical bulletin.

[30]  T. Strovas,et al.  AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery , 2020, SLAS discovery : advancing life sciences R & D.

[31]  S. Mattoo,et al.  A Fluorescence Polarization-Based High-Throughput Screen to Identify the First Small-Molecule Modulators of the Human Adenylyltransferase HYPE/FICD , 2020, International journal of molecular sciences.

[32]  Karunakaran A Kalesh,et al.  Detectives and helpers: Natural products as resources for chemical probes and compound libraries. , 2020, Pharmacology & therapeutics.

[33]  Ilaria Iacobucci,et al.  From classical to new generation approaches: An excursus of -omics methods for investigation of protein-protein interaction networks. , 2020, Journal of proteomics.

[34]  J. Zhao,et al.  Design, Synthesis and Structure-Activity Relationships of Indoline-Based Kelch-like ECH Associated Protein 1-Nuclear Factor (Erythroid-derived 2)-like 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors. , 2020, Journal of medicinal chemistry.

[35]  X. Le,et al.  Aptamer binding assays and molecular interaction studies using fluorescence anisotropy - A review. , 2020, Analytica chimica acta.

[36]  J. Karanicolas,et al.  Identification and Validation of an Aspergillus nidulans Secondary Metabolite Derivative as an Inhibitor of the Musashi-RNA Interaction , 2020, Cancers.

[37]  G. Rudenko,et al.  Discovery of phenanthridine analogues as novel chemical probes disrupting the binding of DNA to ΔFosB homodimers and ΔFosB/JunD heterodimers. , 2020, Bioorganic & medicinal chemistry letters.

[38]  Qingxin Li,et al.  Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery , 2020, International journal of molecular sciences.

[39]  Peng Wu Inhibition of RNA-binding proteins with small molecules , 2020, Nature Reviews Chemistry.

[40]  J. Wade,et al.  Traceable Peptidic Ligands that Target Ghrelin Receptors. , 2020, Current protein & peptide science.

[41]  P. Njogu,et al.  Exploring different approaches to improve the success of drug discovery and development projects: a review , 2020, Future Journal of Pharmaceutical Sciences.

[42]  Yong Chen,et al.  Development and Optimization of a Cascade of Screening Assays for Inhibitors of TRF2. , 2020, Analytical biochemistry.

[43]  L. Dekker,et al.  Use of BODIPY-Labeled ATP Analogues in the Development and Validation of a Fluorescence Polarization-Based Assay for Screening of Kinase Inhibitors , 2020, ACS omega.

[44]  E. Breukink,et al.  Fluorescence anisotropy assays for high throughput screening of compounds binding to lipid II, PBP1b, FtsW and MurJ , 2020, Scientific Reports.

[45]  Rong Huang,et al.  Development of fluorescence polarization-based competition assay for nicotinamide N-methyltransferase , 2020, bioRxiv.

[46]  I. Wilson,et al.  An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen , 2020, Proceedings of the National Academy of Sciences.

[47]  Junjie Zhu,et al.  Structure‐based design, synthesis, and evaluation of Bcl‐2/Mcl‐1 dual inhibitors , 2020, Archiv der Pharmazie.

[48]  Dean G. Brown,et al.  Opportunities and challenges in phenotypic screening for neurodegenerative disease research. , 2020, Journal of medicinal chemistry.

[49]  D. Watt,et al.  Discovery and development of small-molecule inhibitors of glycogen synthase. , 2020, Journal of medicinal chemistry.

[50]  R. Judson,et al.  High-Throughput Screening to Predict Chemical-Assay Interference , 2020, Scientific Reports.

[51]  Ruixiang Li,et al.  Discovery of the anti-angiogenesis effect of eltrombopag in breast cancer through targeting of HuR protein , 2020, Acta pharmaceutica Sinica. B.

[52]  Maria Paola Costi,et al.  Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology , 2020, Journal of medicinal chemistry.

[53]  Emma J. Chory,et al.  A Deep Learning Approach to Antibiotic Discovery , 2020, Cell.

[54]  S. Djordjević,et al.  Discovery of a novel fluorescent chemical probe suitable for evaluation of neuropilin‐1 binding of small molecules , 2020, Drug development research.

[55]  C. Domene,et al.  Mechanism of molecular oxygen diffusion in a hypoxia sensing prolyl hydroxylase using multiscale simulation. , 2020, Journal of the American Chemical Society.

[56]  M. Sattler,et al.  Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery. , 2020, Journal of Medicinal Chemistry.

[57]  Anna K H Hirsch,et al.  Concepts and Core Principles of Fragment-Based Drug Design , 2019, Molecules.

[58]  E. Ortlund,et al.  Development of a Versatile and Sensitive Direct Ligand Binding Assay for Human NR5A Nuclear Receptors. , 2019, ACS medicinal chemistry letters.

[59]  P. Ratcliffe,et al.  Structure‐Activity Relationship and Crystallographic Studies on 4‐Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors , 2019, ChemMedChem.

[60]  T. Schulz,et al.  Fragment-Based Discovery of a Qualified Hit Targeting the Latency-Associated Nuclear Antigen of the Oncogenic Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8. , 2019, Journal of medicinal chemistry.

[61]  Wolfgang Jahnke,et al.  Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures. , 2019, Cell chemical biology.

[62]  Xing Chen,et al.  MicroRNA-small molecule association identification: from experimental results to computational models , 2018, Briefings Bioinform..

[63]  Pia Hansson,et al.  A Comparative Study of Fluorescence Assays in Screening for BRD4. , 2018, Assay and drug development technologies.

[64]  Jing Gu,et al.  Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia. , 2018, Journal of medicinal chemistry.

[65]  Arielle Rowe,et al.  Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery , 2018, International journal of molecular sciences.

[66]  Mukul R Jain,et al.  Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. , 2018, Journal of medicinal chemistry.

[67]  H. Dudek,et al.  Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  Matthias W. Hentze,et al.  A brave new world of RNA-binding proteins , 2018, Nature Reviews Molecular Cell Biology.

[69]  Shaoyong Lu,et al.  Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration. , 2017, Nature chemical biology.

[70]  L. Lavis Teaching Old Dyes New Tricks: Biological Probes Built from Fluoresceins and Rhodamines. , 2017, Annual review of biochemistry.

[71]  Lee A. D. Cooper,et al.  The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies , 2017, Nature Communications.

[72]  Anthony D. Keefe,et al.  DNA-encoded chemistry: enabling the deeper sampling of chemical space , 2016, Nature Reviews Drug Discovery.

[73]  Ajit Jadhav,et al.  Fluorescence polarization assays in high-throughput screening and drug discovery: a review , 2016, Methods and applications in fluorescence.

[74]  Q. You,et al.  Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors. , 2015, ACS medicinal chemistry letters.

[75]  J. Chambers,et al.  Modular chemical probes for visualizing and tracking endogenous ion channels , 2015, Neuropharmacology.

[76]  J. Konvalinka,et al.  Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II. , 2015, Journal of medicinal chemistry.

[77]  E. Nishida,et al.  Dual role of YAP and TAZ in renewal of the intestinal epithelium , 2014, Nature Cell Biology.

[78]  Lu Lu,et al.  Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor , 2014, Nature Communications.

[79]  Christopher J. Contreras,et al.  Structural basis for 2′-phosphate incorporation into glycogen by glycogen synthase , 2013, Proceedings of the National Academy of Sciences.

[80]  Shinya Oishi,et al.  Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[81]  Alexander D. MacKerell,et al.  The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein–protein interactions with Bak , 2013, Molecular Cancer.

[82]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[83]  M. Hall,et al.  HIF-independent role of prolyl hydroxylases in the cellular response to amino acids , 2012, Oncogene.

[84]  A. Kong,et al.  Optimization of Fluorescently Labeled Nrf2 Peptide Probes and the Development of a Fluorescence Polarization Assay for the Discovery of Inhibitors of Keap1-Nrf2 Interaction , 2012, Journal of biomolecular screening.

[85]  R. DuBois,et al.  Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay. , 2012, ACS chemical biology.

[86]  R. Verhaak,et al.  Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.

[87]  Geng Wu,et al.  Structural basis for the recognition of Asef by adenomatous polyposis coli , 2011, Cell Research.

[88]  Anton Simeonov,et al.  Fluorescence polarization assays in small molecule screening , 2011, Expert opinion on drug discovery.

[89]  Thomas D. Pollard,et al.  A Guide to Simple and Informative Binding Assays , 2010, Molecular biology of the cell.

[90]  Stéphanie Pérot,et al.  Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. , 2010, Drug discovery today.

[91]  Erin E. Carlson,et al.  Natural products as chemical probes. , 2010, ACS chemical biology.

[92]  M. Wendt Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein–protein interaction , 2008, Expert opinion on drug discovery.

[93]  Brian J Eastwood,et al.  A Comparison of Assay Performance Measures in Screening Assays: Signal Window, Z' Factor, and Assay Variability Ratio , 2006, Journal of biomolecular screening.

[94]  Rainer Bischoff,et al.  Receptor-ligand binding assays: technologies and applications. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[95]  M. Blank,et al.  Aptamers as tools for target validation. , 2005, Current opinion in chemical biology.

[96]  Hans Clevers,et al.  Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells , 2005, Nature.

[97]  S. Eremin,et al.  Fluorescence polarization immunoassay based on a monoclonal antibody for the detection of ochratoxin A , 2004 .

[98]  Xueliang Fang,et al.  Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. , 2004, Analytical biochemistry.

[99]  G. Wagner,et al.  Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[100]  Ann C Horan,et al.  Use of Red-Shifted Dyes in a Fluorescence Polarization AKT Kinase Assay for Detection of Biological Activity in Natural Product Extracts , 2004, Journal of biomolecular screening.

[101]  S. Cope,et al.  Diagnosis of militarily relevant diseases using oral fluid and saliva antibodies: fluorescence polarization immunoassay. , 2003, Military medicine.

[102]  David K. Johnson Fluorescence polarization immunoassays for metal ions. , 2003, Combinatorial chemistry & high throughput screening.

[103]  K. Ervin,et al.  Development and application of fluorescence polarization assays in drug discovery. , 2003, Combinatorial chemistry & high throughput screening.

[104]  S. Eremin,et al.  Fluorescence polarization immunoassays for pesticides. , 2003, Combinatorial chemistry & high throughput screening.

[105]  D. Earnshaw,et al.  Real Experiences of uHTS: A Prototypic 1536-Well Fluorescence Anisotropy-Based uHTS Screen and Application of Well-Level Quality Control Procedures , 2001, Journal of biomolecular screening.

[106]  J. Owicki,et al.  Fluorescence Polarization and Anisotropy in High Throughput Screening: Perspectives and Primer , 2000, Journal of biomolecular screening.

[107]  D. Jameson,et al.  Quantification of protein-protein interactions using fluorescence polarization. , 1999, Methods.

[108]  A. Saltiel,et al.  The Role of Glucose Metabolites in the Activation and Translocation of Glycogen Synthase by Insulin in 3T3-L1 Adipocytes* , 1999, The Journal of Biological Chemistry.

[109]  Y. Barenholz,et al.  Characterization of liposomes and other lipid assemblies by multiprobe fluorescence polarization. , 1993, Chemistry and physics of lipids.

[110]  E. Fry,et al.  Polarized Light Scattering by Small Particles , 1982 .

[111]  G. Omenn,et al.  Studies of polypeptide structure by fluorescence techniques. III. Interaction between dye and macromolecule in fluorescent conjugates , 1967, Biopolymers.

[112]  G. Weber Polarization of the fluorescence of macromolecules. I. Theory and experimental method. , 1952, The Biochemical journal.

[113]  D. Laurence,et al.  A study of the adsorption of dyes on bovine serum albumin by the method of polarization of fluorescence. , 1952, The Biochemical journal.

[114]  OUP accepted manuscript , 2021, Nucleic Acids Research.

[115]  W. Sippl,et al.  A fluorescence anisotropy-based Myt1 kinase binding assay. , 2014, Assay and drug development technologies.

[116]  Xinyi Huang,et al.  Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. , 2003, Journal of biomolecular screening.